(VCYT) Veracyte - Ratings and Ratios
Cancer Biopsy Tests, Molecular Diagnostics
VCYT EPS (Earnings per Share)
VCYT Revenue
Description: VCYT Veracyte August 10, 2025
Veracyte Inc (NASDAQ:VCYT) is a biotechnology company listed on the NASDAQ stock exchange. The companys stock performance and financial health are critical indicators of its success in the market.
To evaluate VCYTs potential, we need to examine its financials and market metrics. The companys market capitalization stands at approximately $1.96 billion, indicating a significant presence in the biotechnology sector. The price-to-earnings (P/E) ratio is 59.55, suggesting that the stock may be overvalued relative to its current earnings. However, the forward P/E ratio is 18.25, indicating potential for earnings growth.
Key economic drivers for VCYT include the demand for its diagnostic products and the competitive landscape of the biotechnology industry. The companys return on equity (RoE) is 2.83%, which is relatively low, suggesting that the company may not be generating sufficient profits from shareholder equity.
To assess the stocks potential, we can look at key performance indicators (KPIs) such as revenue growth, earnings per share (EPS), and the companys pipeline of new products. A high beta of 1.969 indicates that VCYTs stock price is highly volatile and sensitive to market fluctuations. The stocks current price is $27.37, which is significantly lower than its 52-week high of $46.14, suggesting a potential buying opportunity if the companys fundamentals are strong.
Investors should also consider the companys research and development (R&D) pipeline, regulatory environment, and competition in the biotechnology sector. A thorough analysis of these factors can help determine whether VCYTs stock is likely to appreciate in value. Key drivers to watch include the companys ability to innovate and bring new products to market, as well as its ability to manage costs and improve profitability.
VCYT Stock Overview
| Market Cap in USD | 2,868m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2013-10-30 |
VCYT Stock Ratings
| Growth Rating | 2.24% |
| Fundamental | 57.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.06% |
| Analyst Rating | 4.27 of 5 |
VCYT Dividends
Currently no dividends paidVCYT Growth Ratios
| Growth Correlation 3m | 92.8% |
| Growth Correlation 12m | -48.7% |
| Growth Correlation 5y | -27.6% |
| CAGR 5y | 11.79% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.24 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.58 |
| Sharpe Ratio 12m | 0.03 |
| Alpha | -16.83 |
| Beta | 2.115 |
| Volatility | 50.36% |
| Current Volume | 1160.5k |
| Average Volume 20d | 800.8k |
| Stop Loss | 40 (-4.1%) |
| Signal | 1.45 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (26.3m TTM) > 0 and > 6% of Revenue (6% = 28.7m TTM) |
| FCFTA 0.04 (>2.0%) and ΔFCFTA 0.85pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 70.60% (prev 62.26%; Δ 8.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.07 (>3.0%) and CFO 93.5m > Net Income 26.3m (YES >=105%, WARN >=100%) |
| Net Debt (-168.9m) to EBITDA (58.8m) ratio: -2.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 5.43 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (79.9m) change vs 12m ago 3.55% (target <= -2.0% for YES) |
| Gross Margin 67.31% (prev 65.56%; Δ 1.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 37.16% (prev 32.37%; Δ 4.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 35.8k (EBITDA TTM 58.8m / Interest Expense TTM 1000 ) >= 6 (WARN >= 3) |
Altman Z'' -3.06
| (A) 0.25 = (Total Current Assets 414.7m - Total Current Liabilities 76.4m) / Total Assets 1.34b |
| (B) -0.33 = Retained Earnings (Balance) -437.9m / Total Assets 1.34b |
| (C) 0.03 = EBIT TTM 35.8m / Avg Total Assets 1.29b |
| (D) -3.66 = Book Value of Equity -449.8m / Total Liabilities 123.0m |
| Total Rating: -3.06 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 57.53
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 2.12% = 1.06 |
| 3. FCF Margin 11.52% = 2.88 |
| 4. Debt/Equity 0.04 = 2.50 |
| 5. Debt/Ebitda -2.87 = 2.50 |
| 6. ROIC - WACC (= -9.79)% = -12.24 |
| 7. RoE 2.21% = 0.18 |
| 8. Rev. Trend 97.65% = 7.32 |
| 9. EPS Trend 66.37% = 3.32 |
What is the price of VCYT shares?
Over the past week, the price has changed by +15.58%, over one month by +20.49%, over three months by +50.65% and over the past year by +11.68%.
Is Veracyte a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of VCYT is around 38.49 USD . This means that VCYT is currently overvalued and has a potential downside of -7.7%.
Is VCYT a buy, sell or hold?
- Strong Buy: 7
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the VCYT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 41.1 | -1.4% |
| Analysts Target Price | 41.1 | -1.4% |
| ValueRay Target Price | 44.9 | 7.6% |
VCYT Fundamental Data Overview November 04, 2025
P/E Trailing = 107.2059
P/E Forward = 28.0112
P/S = 5.985
P/B = 2.2956
Beta = 2.115
Revenue TTM = 479.1m USD
EBIT TTM = 35.8m USD
EBITDA TTM = 58.8m USD
Long Term Debt = 50.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.41m USD (from shortTermDebt, last quarter)
Debt = 50.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -168.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.60b USD (2.87b + Debt 50.6m - CCE 320.7m)
Interest Coverage Ratio = 35.8k (Ebit TTM 35.8m / Interest Expense TTM 1000 )
FCF Yield = 2.12% (FCF TTM 55.2m / Enterprise Value 2.60b)
FCF Margin = 11.52% (FCF TTM 55.2m / Revenue TTM 479.1m)
Net Margin = 5.50% (Net Income TTM 26.3m / Revenue TTM 479.1m)
Gross Margin = 67.31% ((Revenue TTM 479.1m - Cost of Revenue TTM 156.6m) / Revenue TTM)
Gross Margin QoQ = 68.97% (prev 69.46%)
Tobins Q-Ratio = 1.93 (Enterprise Value 2.60b / Total Assets 1.34b)
Interest Expense / Debt = 0.00% (Interest Expense 1000 / Debt 50.6m)
Taxrate = 178.4% (out of range, set to none) (2.23m / 1.25m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 5.43 (Total Current Assets 414.7m / Total Current Liabilities 76.4m)
Debt / Equity = 0.04 (Debt 50.6m / totalStockholderEquity, last quarter 1.22b)
Debt / EBITDA = -2.87 (Net Debt -168.9m / EBITDA 58.8m)
Debt / FCF = -3.06 (Net Debt -168.9m / FCF TTM 55.2m)
Total Stockholder Equity = 1.19b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.96% (Net Income 26.3m / Total Assets 1.34b)
RoE = 2.21% (Net Income TTM 26.3m / Total Stockholder Equity 1.19b)
RoCE = 2.88% (EBIT 35.8m / Capital Employed (Equity 1.19b + L.T.Debt 50.6m))
RoIC = 3.78% (EBIT 35.8m / (Assets 1.34b - Curr.Liab 76.4m - Cash 320.7m))
WACC = 13.57% (E(2.87b)/V(2.92b) * Re(13.81%) + (debt cost/tax rate unavailable))
Discount Rate = 13.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 4.55%
[DCF Debug] Terminal Value 55.48% ; FCFE base≈49.2m ; Y1≈40.5m ; Y5≈29.1m
Fair Price DCF = 3.33 (DCF Value 262.2m / Shares Outstanding 78.7m; 5y FCF grow -21.23% → 3.0% )
EPS Correlation: 66.37 | EPS CAGR: 4.65% | SUE: -1.21 | # QB: 0
Revenue Correlation: 97.65 | Revenue CAGR: 21.85% | SUE: 2.54 | # QB: 2
Additional Sources for VCYT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle